YU82702A - Ortosupstituisani amidi antranilne kiseline i njihova primena kao sredstva za lečenje - Google Patents

Ortosupstituisani amidi antranilne kiseline i njihova primena kao sredstva za lečenje

Info

Publication number
YU82702A
YU82702A YU82702A YUP82702A YU82702A YU 82702 A YU82702 A YU 82702A YU 82702 A YU82702 A YU 82702A YU P82702 A YUP82702 A YU P82702A YU 82702 A YU82702 A YU 82702A
Authority
YU
Yugoslavia
Prior art keywords
medicaments
ortho
acid amides
anthranilic acid
substituted anthranilic
Prior art date
Application number
YU82702A
Other languages
English (en)
Inventor
Martin Kruger
Andreas Huth
Orlin Petrov
Dieter Seidelmann
Karl-Heinz Thierauch
Martin Haberey
Andreas Menrad
Alexander Ernst
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of YU82702A publication Critical patent/YU82702A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Opisani su ortosupstituisani amidi antranilne kiseline i njihova primena kao sredstva za lečenje oboljenja, izazvanih perzistentnom angiogenezom.[The invention relates to ortho-substituted anthranilic acid amides and to their use as medicaments for treating medical disorders, which are triggered by persistent angiogenesis.
YU82702A 2000-05-09 2001-05-08 Ortosupstituisani amidi antranilne kiseline i njihova primena kao sredstva za lečenje YU82702A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10023486A DE10023486C1 (de) 2000-05-09 2000-05-09 Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
YU82702A true YU82702A (sh) 2006-05-25

Family

ID=7641923

Family Applications (1)

Application Number Title Priority Date Filing Date
YU82702A YU82702A (sh) 2000-05-09 2001-05-08 Ortosupstituisani amidi antranilne kiseline i njihova primena kao sredstva za lečenje

Country Status (31)

Country Link
US (2) US7081468B2 (sh)
EP (1) EP1280799B1 (sh)
JP (1) JP2003532725A (sh)
KR (1) KR20020094024A (sh)
CN (1) CN1237062C (sh)
AT (1) ATE258174T1 (sh)
AU (2) AU2001274001B2 (sh)
BG (1) BG107261A (sh)
BR (1) BR0110621A (sh)
CA (1) CA2407852A1 (sh)
CZ (1) CZ20023677A3 (sh)
DE (2) DE10023486C1 (sh)
DK (1) DK1280799T3 (sh)
EE (1) EE04938B1 (sh)
ES (1) ES2214424T3 (sh)
HK (1) HK1056728A1 (sh)
HR (1) HRP20020977B1 (sh)
HU (1) HUP0301954A2 (sh)
IL (2) IL152578A0 (sh)
MX (1) MXPA02010915A (sh)
NO (1) NO323541B1 (sh)
NZ (1) NZ521700A (sh)
PL (1) PL358204A1 (sh)
PT (1) PT1280799E (sh)
RU (1) RU2264399C2 (sh)
SK (1) SK15882002A3 (sh)
TR (1) TR200400912T4 (sh)
UA (1) UA73187C2 (sh)
WO (1) WO2001085719A1 (sh)
YU (1) YU82702A (sh)
ZA (1) ZA200209896B (sh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10023486C1 (de) * 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
DE10023484A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20030134836A1 (en) * 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
MXPA04012948A (es) * 2002-07-31 2005-09-12 Schering Ag Inhibidores antranilamidopiridinas vegfr-2 y vegfr-3.
US20050004133A1 (en) * 2003-06-05 2005-01-06 Makings Lewis R. Modulators of VR1 receptor
US7202260B2 (en) 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
DE10327719A1 (de) * 2003-06-13 2005-01-20 Schering Ag VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
CA2539549A1 (en) 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
DE102004011720B4 (de) * 2004-03-10 2008-04-03 Bayer Schering Pharma Aktiengesellschaft Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie
US7427390B2 (en) * 2004-03-10 2008-09-23 Schering Ag Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
KR20080071562A (ko) * 2005-11-30 2008-08-04 아스텔라스세이야쿠 가부시키가이샤 ２-아미노벤즈아미드 유도체
CU24389B1 (es) 2014-01-13 2019-04-04 Aurigene Discovery Tech Ltd Compuestos de heterociclilo bicíclico como inhibidores de irak4
JP2017518348A (ja) * 2014-06-20 2017-07-06 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｉｒａｋ４阻害剤としての置換インダゾール化合物
HRP20230657T8 (hr) 2017-03-31 2023-11-10 Aurigene Oncology Limited Spojevi i pripravci za liječenje hematoloških poremećaja
IL315025A (en) 2017-10-31 2024-10-01 Curis Inc Compounds and preparations for the treatment of hematological disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409668A (en) * 1964-11-07 1968-11-05 Palazzo Giuseppe Substituted anthranilamides and process for the preparation thereof
FR2689508B1 (fr) * 1992-04-01 1994-06-17 Fournier Ind & Sante Derives de l'imidazole, leur procede de preparation et leur application en therapeutique.
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
DE10023492A1 (de) * 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
DE10023484A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
DE10023486C1 (de) * 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
EP1392680B1 (de) * 2001-05-08 2009-07-22 Bayer Schering Pharma Aktiengesellschaft Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren
US20040039019A1 (en) * 2002-06-19 2004-02-26 Schering Ag Selected anthranilaminde pyridinamides and their use as pharmaceutical agents
US7615565B2 (en) * 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7517894B2 (en) * 2002-07-31 2009-04-14 Bayer Schering Pharma Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7202260B2 (en) * 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
CA2574366A1 (en) * 2004-07-19 2006-01-26 Thia Medica As Composition comprising plant and/or fish oils and compounds comprising non-oxidizable fatty acid entities
EP1655295A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1657241A1 (en) * 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) * 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
US20060266770A1 (en) * 2005-05-26 2006-11-30 Fitzgerald Robert M Portable dispensers comprising a mobile dispenser and mobile storage cartridge

Also Published As

Publication number Publication date
EP1280799A1 (de) 2003-02-05
KR20020094024A (ko) 2002-12-16
EP1280799B1 (de) 2004-01-21
HRP20020977A2 (en) 2005-02-28
WO2001085719A9 (de) 2001-12-27
PL358204A1 (en) 2004-08-09
US7081468B2 (en) 2006-07-25
US20060014747A1 (en) 2006-01-19
NO323541B1 (no) 2007-06-11
MXPA02010915A (es) 2003-07-14
ZA200209896B (en) 2004-03-05
US20040102441A1 (en) 2004-05-27
JP2003532725A (ja) 2003-11-05
HUP0301954A2 (hu) 2003-09-29
RU2264399C2 (ru) 2005-11-20
CA2407852A1 (en) 2001-11-15
ES2214424T3 (es) 2004-09-16
BG107261A (bg) 2003-06-30
NO20025358D0 (no) 2002-11-08
SK15882002A3 (sk) 2003-08-05
TR200400912T4 (tr) 2004-07-21
DK1280799T3 (da) 2004-05-10
IL152578A (en) 2008-11-03
EE04938B1 (et) 2007-12-17
CN1427837A (zh) 2003-07-02
NO20025358L (no) 2002-11-08
ATE258174T1 (de) 2004-02-15
NZ521700A (en) 2005-09-30
EE200200625A (et) 2004-04-15
DE50101364D1 (de) 2004-02-26
BR0110621A (pt) 2003-03-25
CN1237062C (zh) 2006-01-18
PT1280799E (pt) 2004-06-30
WO2001085719A1 (de) 2001-11-15
IL152578A0 (en) 2003-05-29
DE10023486C1 (de) 2002-03-14
UA73187C2 (en) 2005-06-15
AU2001274001B2 (en) 2007-01-18
CZ20023677A3 (cs) 2003-02-12
HK1056728A1 (en) 2004-02-27
HRP20020977B1 (en) 2008-05-31
AU7400101A (en) 2001-11-20

Similar Documents

Publication Publication Date Title
YU82702A (sh) Ortosupstituisani amidi antranilne kiseline i njihova primena kao sredstva za lečenje
YU31801A (sh) Amidi antranilne kiseline i njihova upotreba kao leka
NZ521681A (en) Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
WO2001085715A3 (de) Aza- und polyazanthranylamide und deren verwendung als arzneimittel
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
TW200505837A (en) Novel compounds
TW200519075A (en) Novel compounds
GB0222495D0 (en) Compounds
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
MXPA03005340A (es) Nuevas composiciones de medicamentos a base de anticolinergicos y ciclesonida.
GB0111186D0 (en) Novel compounds
WO2002007669A3 (en) Phospholipid derivatives of valproic acid and mixtures thereof
MY124786A (en) Bis-arylsulfones
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
IL161116A0 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
MXPA05013586A (es) Antranilamidopiridonas que inhiben vegfr-2 y vegfr-3.
GB0128071D0 (en) Medicament
MXPA04000953A (es) Derivados sustituidos del acido 5,6,6a,11b-tetrahidro-7-oxa-aza-benzo[c]fluoren-6-carboxilico como antagonista de nmda.
ZA200308097B (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes.
MXPA04003938A (es) Compuestos retinoides heterociclicos.
WO2002007766A3 (en) Use of d5-dopamine receptor agonists in the manufacture of a medicament for the treatment of dyskinesia
WO2000051684A3 (en) Regulators of coenzyme-a-independent transacylase as psychotropic drugs